<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ACANYA- clindamycin phosphate and benzoyl peroxide gel </strong><br>Coria Laboratories<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use ACANYA Gel safely and effectively. See full prescribing information for ACANYA Gel. <br>   <br>ACANYA<span class="Sup">®</span><br>(clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/2.5% <br>For topical use<br><br>Initial U.S. Approval: 2000</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">ACANYA Gel is a lincosamide antibiotic and benzoyl peroxide indicated for the topical treatment of <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne vulgaris</span>. (<a href="#S1">1</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>Apply a pea-sized amount of ACANYA Gel to the face once daily. (<a href="#S2">2</a>)</li>
<li>Not for oral, ophthalmic, or intravaginal use. (<a href="#S2">2</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">ACANYA Gel contains clindamycin phosphate 1.2% and benzoyl peroxide 2.5% in a topical gel in 50 gram pumps. (<a href="#S3">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div>
<p class="Highlighta">ACANYA Gel is contraindicated in: </p>
<ul>
<li>Patients who have demonstrated <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (e.g., <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>) to clindamycin, benzoyl peroxide, any components of the formulation, or lincomycin. (<a href="#S4">4</a>)</li>
<li>Patients with a history of <span class="product-label-link" type="condition" conceptid="201606" conceptname="Crohn's disease">regional enteritis</span>, <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>, or antibiotic-associated <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. (<a href="#S4">4</a>)</li>
</ul>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li><span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">Colitis</span>:  Orally and parenterally administered clindamycin has been associated with severe <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, which may result in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> (including <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span>) have been reported with the use of topical and systemic clindamycin. ACANYA Gel should be discontinued if significant <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> occurs. (<a href="#S5.1">5.1</a>)</li>
<li>Ultraviolet Light and Environmental Exposure:  Minimize sun exposure following drug application. (<a href="#S5.2">5.2</a>)</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The following selected adverse reactions occurred in less than 0.2% of patients: <span class="product-label-link" type="condition" conceptid="4319311" conceptname="Application site pain">application site pain</span> (0.1%); application site <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">exfoliation</span> (0.1%); and <span class="product-label-link" type="condition" conceptid="4318383" conceptname="Application site irritation">application site irritation</span> (0.1%). (<a href="#S6.1">6.1</a>) </p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Valeant Pharmaceuticals North America LLC, at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch</span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul><li>ACANYA Gel should not be used in combination with erythromycin-containing products because of its clindamycin component. (<a href="#S7.1">7.1</a>)</li></ul></div>
<div></div>
<div></div>
</div>
<div>
<div><div></div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 2/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h2><a href="#section-4.1" class="toc">4.1	<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></a></h2>
<h2><a href="#section-4.2" class="toc">4.2	<span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">Colitis</span>/<span class="product-label-link" type="condition" conceptid="201773" conceptname="Enteritis of small intestine">Enteritis</span></a></h2>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1	<span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">Colitis</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2	Ultraviolet Light and Environmental Exposure  </a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1	Clinical Studies Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2	Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1	Erythromycin</a></h2>
<h2><a href="#section-7.2" class="toc">7.2	Neuromuscular Blocking Agents</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3	Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-10" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-10.1" class="toc">12.1 Mechanisms of Action</a></h2>
<h2><a href="#section-10.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-10.3" class="toc">12.4	Microbiology</a></h2>
<h1><a href="#section-11" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-12" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-13" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-13.1" class="toc">16.1	How Supplied</a></h2>
<h2><a href="#section-13.2" class="toc">16.2	Dispensing Instructions for the Pharmacist</a></h2>
<h2><a href="#section-13.3" class="toc">16.3	Storage and Handling</a></h2>
<h1><a href="#section-14" class="toc">17	PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">ACANYA<span class="Sup">®</span> Gel is indicated for the topical treatment of <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne vulgaris</span> in patients 12 years or older.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">Apply a pea-sized amount of ACANYA Gel to the face once daily. </p>
<p>Use of ACANYA Gel beyond 12 weeks has not been evaluated.</p>
<p>Concomitant topical <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> therapy should be used with caution because a possible cumulative irritancy effect may occur, especially with the use of <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span>, desquamating, or abrasive agents.</p>
<p>ACANYA Gel is not for oral, ophthalmic, or intravaginal use.</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Gel, 1.2%/2.5%</p>
<p>Each gram of ACANYA Gel contains 10 mg (1%) clindamycin as phosphate, and 25 mg (2.5%) benzoyl peroxide in a white to off-white, opaque, smooth gel.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S4.1"></a><a name="section-4.1"></a><p></p>
<h2>4.1	<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></h2>
<p class="First">ACANYA Gel is contraindicated in those individuals who have shown <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to clindamycin, benzoyl peroxide, any components of the formulation, or lincomycin. <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span>, as well as <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> leading to hospitalization, has been reported in postmarketing use with ACANYA Gel [see <span class="Italics"><a href="#S6.2">Postmarketing Experience (6.2)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S4.2"></a><a name="section-4.2"></a><p></p>
<h2>4.2	<span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">Colitis</span>/<span class="product-label-link" type="condition" conceptid="201773" conceptname="Enteritis of small intestine">Enteritis</span></h2>
<p class="First">ACANYA Gel is contraindicated in patients with a history of <span class="product-label-link" type="condition" conceptid="201606" conceptname="Crohn's disease">regional enteritis</span>, <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>, or antibiotic-associated <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> [see <span class="Italics"><a href="#S5.1">Warnings and Precautions (5.1)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1	<span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">Colitis</span></h2>
<p class="First">Systemic absorption of clindamycin has been demonstrated following topical use of clindamycin.  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> (including <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span>) have been reported with the use of topical and systemic clindamycin. When significant <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> occurs, ACANYA Gel should be discontinued.</p>
<p>Severe <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> has occurred following oral and parenteral administration of clindamycin with an onset of up to several weeks following cessation of therapy.  Antiperistaltic agents such as opiates and diphenoxylate with atropine may prolong and/or worsen severe <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>.  Severe <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> may result in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
<p>Studies indicate toxin(s) produced by Clostridia is one primary cause of antibiotic-associated <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. The <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> is usually characterized by severe persistent <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and severe <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span> and may be associated with the passage of blood and mucus. Stool cultures for <span class="Italics">Clostridium difficile</span> and stool assay for <span class="Italics">C. difficile</span> toxin may be helpful diagnostically.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2	Ultraviolet Light and Environmental Exposure  </h2>
<p class="First">Minimize sun exposure including use of tanning beds or sun lamps following drug application [<span class="Italics">see <a href="#S13.1">Nonclinical Toxicology (13.1)</a></span>]<span class="Italics">.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1	Clinical Studies Experience</h2>
<p class="First">Because clinical trials are conducted under prescribed conditions, adverse reaction rates observed in the clinical trial may not reflect the rates observed in practice. Because clinical trials are also conducted under widely varying conditions, adverse reactions observed in the clinical trials of a drug cannot always be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>The following selected adverse reactions occurred in less than 0.2% of patients treated with ACANYA Gel: <span class="product-label-link" type="condition" conceptid="4319311" conceptname="Application site pain">application site pain</span> (0.1%); application site <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">exfoliation</span> (0.1%); and <span class="product-label-link" type="condition" conceptid="4318383" conceptname="Application site irritation">application site irritation</span> (0.1%).</p>
<p>During clinical trials, subjects were assessed for local cutaneous signs and symptoms of <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, scaling, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, burning and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span>. Most local <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> increased and peaked around week 4 and continually decreased over time reaching near baseline levels by week 12. The percentage of subjects that had symptoms present before treatment, the maximum value recorded during treatment, and the percent with symptoms present at week 12 are shown in Table 1.</p>
<table width="85%">
<caption><span>Table 1: Local <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span> - Percent of Subjects with Symptoms Present. Combined Results from the Two Phase 3 Trials (N = 773) </span></caption>
<col align="left" valign="middle" width="10%">
<col align="center" valign="middle" width="10%">
<col align="center" valign="middle" width="10%">
<col align="center" valign="middle" width="10%">
<col align="center" valign="middle" width="10%">
<col align="center" valign="middle" width="10%">
<col align="center" valign="middle" width="10%">
<col align="center" valign="middle" width="10%">
<col align="center" valign="middle" width="10%">
<col align="center" valign="middle" width="10%">
<thead>
<tr class="First">
<th class="Lrule" align="left"></th>
<th class="Botrule Lrule" align="center" colspan="3">Before Treatment <br>(Baseline)</th>
<th class="Botrule Lrule" align="center" colspan="3">Maximum During  <br>Treatment</th>
<th class="Botrule Lrule Rrule" align="center" colspan="3">End of Treatment <br>(Week 12)</th>
</tr>
<tr class="Last">
<th class="Lrule" align="left"></th>
<th class="Lrule" align="center">Mild</th>
<th align="center">Mod.<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</th>
<th align="center">Severe</th>
<th class="Lrule" align="center">Mild</th>
<th align="center">Mod.<a href="#footnote-1" class="Sup">*</a>
</th>
<th align="center">Severe</th>
<th class="Lrule" align="center">Mild</th>
<th align="center">Mod.<a href="#footnote-1" class="Sup">*</a>
</th>
<th class="Rrule" align="center">Severe</th>
</tr>
</thead>
<tfoot><tr><td colspan="10" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Mod. = Moderate</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span></td>
<td class="Lrule" align="center">22</td>
<td align="center">4</td>
<td align="center">0</td>
<td class="Lrule" align="center">25</td>
<td align="center">5</td>
<td align="center">&lt; 1</td>
<td class="Lrule" align="center">15</td>
<td align="center">2</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule" align="left">  Scaling</td>
<td class="Lrule" align="center">8</td>
<td align="center">&lt; 1</td>
<td align="center">0</td>
<td class="Lrule" align="center">18</td>
<td align="center">3</td>
<td align="center">0</td>
<td class="Lrule" align="center">8</td>
<td align="center">1</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">Itching</span></td>
<td class="Lrule" align="center">10</td>
<td align="center">2</td>
<td align="center">0</td>
<td class="Lrule" align="center">15</td>
<td align="center">2</td>
<td align="center">0</td>
<td class="Lrule" align="center">6</td>
<td align="center">&lt; 1</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule" align="left">  Burning</td>
<td class="Lrule" align="center">3</td>
<td align="center">&lt; 1</td>
<td align="center">0</td>
<td class="Lrule" align="center">8</td>
<td align="center">2</td>
<td align="center">0</td>
<td class="Lrule" align="center">2</td>
<td align="center">&lt; 1</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Stinging</span></td>
<td class="Lrule" align="center">2</td>
<td align="center">&lt; 1</td>
<td align="center">0</td>
<td class="Lrule" align="center">6</td>
<td align="center">1</td>
<td align="center">0</td>
<td class="Lrule" align="center">1</td>
<td align="center">&lt; 1</td>
<td class="Rrule" align="center">0</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2	Postmarketing Experience</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span>, as well as <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> leading to hospitalizations, has been reported in postmarketing use of products containing clindamycin/benzoyl peroxide.</p>
<p>Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1	Erythromycin</h2>
<p class="First">ACANYA Gel should not be used in combination with topical or oral erythromycin-containing products due to its clindamycin component. <span class="Italics">In vitro</span> studies have shown antagonism between erythromycin and clindamycin. The clinical significance of this <span class="Italics">in vitro</span> antagonism is not known.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2	Neuromuscular Blocking Agents</h2>
<p class="First">Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore, ACANYA Gel should be used with caution in patients receiving such agents. </p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.1.1"></a><p></p>
<p class="First">Pregnancy Category C.</p>
<p>There are no adequate and well-controlled studies in pregnant women treated with ACANYA Gel. ACANYA Gel should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p>Animal reproductive/developmental toxicity studies have not been conducted with ACANYA Gel or benzoyl peroxide. Developmental toxicity studies of clindamycin performed in rats and mice using oral doses of up to 600 mg/kg/day (240 and 120 times amount of clindamycin in the highest recommended adult human dose based on mg/m<span class="Sup">2</span>, respectively) or subcutaneous doses of up to 200 mg/kg/day (80 and 40 times the amount of clindamycin in the highest recommended adult human dose based on mg/m<span class="Sup">2</span>, respectively) revealed no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3	Nursing Mothers</h2>
<p class="First">It is not known whether clindamycin is excreted in human milk after topical application of ACANYA Gel. However, orally and parenterally administered clindamycin has been reported to appear in breast milk. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to use ACANYA Gel while nursing, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness of ACANYA Gel in pediatric patients under the age of 12 have not been evaluated. </p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical trials of ACANYA Gel did not include sufficient numbers of subjects aged 65 and older to determine whether they respond differently from younger subjects.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-9"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">ACANYA (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/2.5% is a combination product with two active ingredients in an aqueous gel formulation intended for topical use. Clindamycin phosphate is a water-soluble ester of the semi-synthetic antibiotic produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent antibiotic lincomycin.</p>
<p>The chemical name for clindamycin phosphate is <span class="Italics">Methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-threo-</span><span class="Italics">α</span><span class="Italics">-D-galacto-octopyranoside 2</span>-(dihydrogen phosphate). The structural formula for clindamycin phosphate is represented below:</p>
<p>Clindamycin phosphate:</p>
<p><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3dcd2c96-72b1-4a9f-b65c-08198d63b7df&amp;name=acanya-01.jpg"></p>
<p>Molecular Formula: C<span class="Sub">18</span>H<span class="Sub">34</span>ClN<span class="Sub">2</span>O<span class="Sub">8</span>PS          Molecular Weight: 504.97</p>
<p>Benzoyl peroxide is an antibacterial and keratolytic agent.  The structural formula for benzoyl peroxide is represented below:</p>
<p>Benzoyl peroxide:</p>
<p><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3dcd2c96-72b1-4a9f-b65c-08198d63b7df&amp;name=acanya-02.jpg"></p>
<p>Molecular Formula: C<span class="Sub">14</span>H<span class="Sub">10</span>O<span class="Sub">4</span>          Molecular Weight: 242.23</p>
<p>ACANYA Gel contains the following inactive ingredients: purified water, carbomer 980, propylene glycol, and potassium hydroxide.  Each gram of ACANYA Gel contains 1.2% of clindamycin phosphate which is equivalent to 1% clindamycin.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-10"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-10.1"></a><p></p>
<h2>12.1 Mechanisms of Action</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1.1"></a><p></p>
<p class="First"><span class="Italics">Clindamycin:</span> Clindamycin is a lincosamide antibacterial [see <span class="Italics"><a href="#S12.4">Microbiology (12.4)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1.2"></a><p></p>
<p class="First"><span class="Italics">Benzoyl Peroxide: Benzoyl peroxide is an oxidizing agent with bacteriocidal and keratolytic effects but the precise mechanism of action is unknown.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-10.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">The systemic absorption of clindamycin was investigated in an open-label, multiple-dose trial in 16 adult subjects with moderate to severe <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne vulgaris</span> treated with 1 gram of ACANYA Gel applied to the face once daily for 30 days. Twelve subjects (75%) had at least one quantifiable clindamycin plasma concentration above the lower limit of quantification (LOQ = 0.5 ng/mL) on Day 1 or Day 30. On Day 1, the mean (± standard deviation) peak plasma concentrations (C<span class="Sub">max</span>) was 0.78 ± 0.22 ng/mL (n=9 with measurable concentrations), and the mean AUC<span class="Sub">0-t</span> was 5.29 ± 0.81 h.ng/mL (n=4). On Day 30, the mean C<span class="Sub">max</span> was 1.22 ± 0.88 ng/mL (n=10), and the mean AUC<span class="Sub">0-t</span> was 8.42 ± 6.01 h.ng/mL (n=6). Clindamycin plasma concentrations were below LOQ in all subjects at 24 hours post-dose on the three tested days (Day 1, 15, and 30). </p>
<p>Benzoyl peroxide has been shown to be absorbed by the skin where it is converted to benzoic acid.</p>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="S12.4"></a><a name="section-10.3"></a><p></p>
<h2>12.4	Microbiology</h2>
<p class="First">Clindamycin binds to the 50S ribosomal subunits of susceptible bacteria and prevents elongation of peptide chains by interfering with peptidyl transfer, thereby suppressing bacterial protein synthesis.</p>
<p>Clindamycin and benzoyl peroxide individually have been shown to have<span class="Italics"> in vitro</span> activity against <span class="Italics">Propionibacterium <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acnes</span></span>, an organism which has been associated with <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne vulgaris</span>; however, the clinical significance of this activity against <span class="Italics">P. <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acnes</span></span> is not known.</p>
<p><span class="Italics">P. <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acnes</span></span> resistance to clindamycin has been documented. Resistance to clindamycin is often associated with resistance to erythromycin.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-11"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-11.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Carcinogenicity, mutagenicity and impairment of fertility testing of ACANYA Gel have not been performed.</p>
<p>Benzoyl peroxide has been shown to be a tumor promoter and progression agent in a number of animal studies. Benzoyl peroxide in acetone at doses of 5 and 10 mg administered topically twice per week for 20 weeks induced <span class="product-label-link" type="condition" conceptid="135777" conceptname="Neoplasm of uncertain behavior of skin">skin tumors</span> in transgenic Tg.AC mice. The clinical significance of this is unknown.</p>
<p>Carcinogenicity studies have been conducted with a gel formulation containing 1% clindamycin and 5% benzoyl peroxide. In a 2-year dermal carcinogenicity study in mice, treatment with the gel formulation at doses of 900, 2700, and 15000 mg/kg/day (1.8, 5.4, and 30 times amount of clindamycin and 3.6, 10.8, and 60 times amount of benzoyl peroxide in the highest recommended adult human dose of 2.5 g ACANYA Gel based on mg/m<span class="Sup">2</span>, respectively) did not cause any increase in tumors. However, topical treatment with  a different gel formulation containing 1% clindamycin and 5% benzoyl peroxide at doses of 100, 500, and 2000 mg/kg/day caused a dose-dependent increase in the incidence of <span class="product-label-link" type="condition" conceptid="4112746" conceptname="Keratoacanthoma">keratoacanthoma</span> at the treated skin site of male rats in a 2-year dermal carcinogenicity study in rats. In an oral (gavage) carcinogenicity study in rats, treatment with the gel formulation at doses of 300, 900 and 3000 mg/kg/day (1.2, 3.6, and 12 times amount of clindamycin and 2.4, 7.2, and 24 times amount of benzoyl peroxide in the highest recommended adult human dose of 2.5 g ACANYA Gel based on mg/m<span class="Sup">2</span>, respectively) for up to 97 weeks did not cause any increase in tumors. In a 52-week dermal photocarcinogenicity study in hairless mice, (40 weeks of treatment followed by 12 weeks of observation), the median time to onset of <span class="product-label-link" type="condition" conceptid="135777" conceptname="Neoplasm of uncertain behavior of skin">skin tumor</span> formation decreased and the number of tumors per mouse increased relative to controls following chronic concurrent topical administration of the higher concentration benzoyl peroxide formulation (5000 and 10000 mg/kg/day, 5 days/week) and exposure to ultraviolet radiation.</p>
<p>Clindamycin phosphate was not genotoxic in the human lymphocyte chromosome aberration assay. Benzoyl peroxide has been found to cause DNA strand breaks in a variety of mammalian cell types, to be mutagenic in <span class="Italics">S. typhimurium </span>tests by some but not all investigators, and to cause sister chromatid exchanges in Chinese hamster ovary cells.</p>
<p>Fertility studies have not been performed with ACANYA Gel or benzoyl peroxide, but fertility and mating ability have been studied with clindamycin. Fertility studies in rats treated orally with up to 300 mg/kg/day of clindamycin (approximately 120 times the amount of clindamycin in the highest recommended adult human dose of 2.5 g ACANYA Gel, based on mg/m<span class="Sup">2</span>) revealed no effects on fertility or mating ability.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-12"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">The safety and efficacy of once daily use of ACANYA Gel were assessed in two 12-week multi-center, randomized, blinded trials in subjects 12 years and older with moderate to severe <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne vulgaris</span>. The two trials were identical in design and compared ACANYA Gel to clindamycin in the vehicle gel, benzoyl peroxide in the vehicle gel, and the vehicle gel alone. </p>
<p>The co-primary efficacy variables were:</p>
<dl>
<dt>(1)</dt>
<dd> Mean absolute change from baseline at week 12 in <ul class="Disc">
<li>Inflammatory lesion counts</li>
<li>Non-inflammatory lesion counts</li>
</ul>
</dd>
<dt>(2)</dt>
<dd> Percent of subjects who had a two grade improvement from baseline on an Evaluator's Global Severity (EGS) score.</dd>
</dl>
<p>The EGS scoring scale used in all of the clinical trials for ACANYA Gel is as follows:</p>
<table width="75%">
<col align="left" valign="top" width="30%">
<col align="left" valign="top" width="70%">
<thead><tr class="First Last">
<th class="Lrule" align="center">Grade</th>
<th class="Lrule Rrule" align="center">Description</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule" align="left">Clear</td>
<td class="Lrule Rrule" align="left">Normal, clear skin with no evidence of <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne vulgaris</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">Almost Clear</td>
<td class="Lrule Rrule" align="left">Rare non-inflammatory lesions present, with rare non-inflamed <span class="product-label-link" type="condition" conceptid="4105835" conceptname="Papule">papules</span> (<span class="product-label-link" type="condition" conceptid="4105835" conceptname="Papule">papules</span> must be resolving and may be hyperpigmented, though not pink-red)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">Mild</td>
<td class="Lrule Rrule" align="left">Some non-inflammatory lesions are present, with few inflammatory lesions (<span class="product-label-link" type="condition" conceptid="4105835" conceptname="Papule">papules</span>/<span class="product-label-link" type="condition" conceptid="4158333" conceptname="Pustule">pustules</span> only; no nodulocystic lesions)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">Moderate</td>
<td class="Lrule Rrule" align="left">Non-inflammatory lesions predominate, with multiple inflammatory lesions evident: several to many comedones and <span class="product-label-link" type="condition" conceptid="4105835" conceptname="Papule">papules</span>/<span class="product-label-link" type="condition" conceptid="4158333" conceptname="Pustule">pustules</span>, and there may or may not be one small nodulo-cystic lesion</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">Severe</td>
<td class="Lrule Rrule" align="left">Inflammatory lesions are more apparent, many comedones and <span class="product-label-link" type="condition" conceptid="4105835" conceptname="Papule">papules</span>/<span class="product-label-link" type="condition" conceptid="4158333" conceptname="Pustule">pustules</span>, there may or may not be a few nodulocystic lesions</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left">Very Severe</td>
<td class="Lrule Rrule" align="left">Highly inflammatory lesions predominate, variable number of comedones, many <span class="product-label-link" type="condition" conceptid="4105835" conceptname="Papule">papules</span>/<span class="product-label-link" type="condition" conceptid="4158333" conceptname="Pustule">pustules</span> and many nodulocystic lesions</td>
</tr>
</tbody>
</table>
<p>The results of Trial 1 at week 12 are presented in Table 2:</p>
<table width="85%">
<caption><span>Table 2: Trial 1 Results</span></caption>
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<thead>
<tr class="First">
<th class="Lrule" align="center" valign="top">Trial 1</th>
<th class="Lrule" align="center" valign="top">ACANYA <br>Gel</th>
<th class="Lrule" align="center" valign="top">Clindamycin <br>Gel</th>
<th class="Lrule" align="center" valign="top">Benzoyl <br>Peroxide <br>Gel</th>
<th class="Lrule Rrule" align="center" valign="top">Vehicle <br>Gel</th>
</tr>
<tr class="Last">
<th class="Lrule" align="center"></th>
<th class="Lrule" align="center" valign="bottom">N = 399</th>
<th class="Lrule" align="center" valign="bottom">N = 408</th>
<th class="Lrule" align="center" valign="bottom">N = 406</th>
<th class="Lrule Rrule" align="center" valign="bottom">N = 201</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Lrule" align="center"><span class="Bold">EGSS Clear or Almost Clear</span></td>
<td class="Lrule" align="center">115 (29%)</td>
<td class="Lrule" align="center">84 (21%)</td>
<td class="Lrule" align="center">76 (19%)</td>
<td class="Lrule Rrule" align="center">29 (14%)</td>
</tr>
<tr>
<td class="Lrule" align="center"><span class="Bold">-----------------</span></td>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center"><span class="Bold">2 grade reduction from baseline</span></td>
<td class="Lrule" align="center">131 (33%)</td>
<td class="Lrule" align="center">100 (25%)</td>
<td class="Lrule" align="center">96 (24%)</td>
<td class="Lrule Rrule" align="center">38 (19%)</td>
</tr>
<tr>
<td class="Lrule" align="center"><span class="Bold">Inflammatory Lesions:</span></td>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="center">  Mean <br>  absolute <br>  change</td>
<td class="Lrule" align="center">14.8</td>
<td class="Lrule" align="center">12.2</td>
<td class="Lrule" align="center">13.0</td>
<td class="Lrule Rrule" align="center">9.0</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">  Mean <br>  percent (%) <br>  reduction</td>
<td class="Lrule" align="center">55.0%</td>
<td class="Lrule" align="center">47.1%</td>
<td class="Lrule" align="center">49.3%</td>
<td class="Lrule Rrule" align="center">34.5%</td>
</tr>
<tr>
<td class="Lrule" align="center"><span class="Bold">Non-Inflammatory Lesions:</span></td>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="center">  Mean <br>  absolute <br>  change</td>
<td class="Lrule" align="center">22.1</td>
<td class="Lrule" align="center">17.9</td>
<td class="Lrule" align="center">20.6</td>
<td class="Lrule Rrule" align="center">13.2</td>
</tr>
<tr class="Last">
<td class="Lrule" align="center">  Mean <br>  percent (%) <br>  reduction</td>
<td class="Lrule" align="center">45.3%</td>
<td class="Lrule" align="center">38.0%</td>
<td class="Lrule" align="center">40.2%</td>
<td class="Lrule Rrule" align="center">28.6%</td>
</tr>
</tbody>
</table>
<p>The results of Trial 2 at week 12 are presented in Table 3:</p>
<table width="95%">
<caption><span>Table 3: Trial 2 Results</span></caption>
<col align="center" valign="middle" width="35%">
<col align="center" valign="middle" width="15%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="15%">
<col align="center" valign="middle" width="15%">
<thead>
<tr class="First">
<th class="Lrule" align="center" valign="top">Trial 2</th>
<th class="Lrule" align="center" valign="top">ACANYA <br>Gel</th>
<th class="Lrule" align="center" valign="middle">Clindamycin Gel</th>
<th class="Lrule" align="center" valign="top">Benzoyl <br>Peroxide <br>Gel</th>
<th class="Lrule Rrule" align="center" valign="middle">Vehicle Gel</th>
</tr>
<tr class="Last">
<th class="Lrule" align="center"></th>
<th class="Lrule" align="center" valign="bottom">N = 398</th>
<th class="Lrule" align="center" valign="bottom">N = 404</th>
<th class="Lrule" align="center" valign="bottom">N = 403</th>
<th class="Lrule Rrule" align="center" valign="bottom">N = 194</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Lrule" align="center"><span class="Bold">EGSS <br>Clear or Almost Clear</span></td>
<td class="Lrule" align="center">113 (28%)</td>
<td class="Lrule" align="center">94 (23%)</td>
<td class="Lrule" align="center">94 (23%)</td>
<td class="Lrule Rrule" align="center">21 (11%)</td>
</tr>
<tr>
<td class="Lrule" align="center"><span class="Bold">-------------------------------</span></td>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center"><span class="Bold">2 grade reduction from baseline</span></td>
<td class="Lrule" align="center">147 (37%)</td>
<td class="Lrule" align="center">114 (28%)</td>
<td class="Lrule" align="center">114 (28%)</td>
<td class="Lrule Rrule" align="center">27 (14%)</td>
</tr>
<tr>
<td class="Lrule" align="center"><span class="Bold">Inflammatory Lesions:</span></td>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="center">  Mean absolute change</td>
<td class="Lrule" align="center">13.7</td>
<td class="Lrule" align="center">11.3</td>
<td class="Lrule" align="center">11.2</td>
<td class="Lrule Rrule" align="center">5.7</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">  Mean percent (%) reduction</td>
<td class="Lrule" align="center">54.2%</td>
<td class="Lrule" align="center">45.3%</td>
<td class="Lrule" align="center">45.7%</td>
<td class="Lrule Rrule" align="center">23.3%</td>
</tr>
<tr>
<td class="Lrule" align="center">
<span class="Bold">Non-Inflammatory Lesions</span>:</td>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="center">  Mean absolute change</td>
<td class="Lrule" align="center">19.0</td>
<td class="Lrule" align="center">14.9</td>
<td class="Lrule" align="center">15.2</td>
<td class="Lrule Rrule" align="center">8.3</td>
</tr>
<tr class="Last">
<td class="Lrule" align="center">  Mean percent (%) reduction</td>
<td class="Lrule" align="center">41.2%</td>
<td class="Lrule" align="center">34.3%</td>
<td class="Lrule" align="center">34.5%</td>
<td class="Lrule Rrule" align="center">19.2%</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-13"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S16.1"></a><a name="section-13.1"></a><p></p>
<h2>16.1	How Supplied</h2>
<p class="First">ACANYA Gel is supplied as a 50 g pump (NDC 13548-132-50).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S16.2"></a><a name="section-13.2"></a><p></p>
<h2>16.2	Dispensing Instructions for the Pharmacist</h2>
<ul>
<li>Dispense ACANYA Gel with a 10 week expiration date.</li>
<li>Specify "Store at room temperature up to 25°C (77°F). Do not freeze."</li>
</ul>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="section-13.3"></a><p></p>
<h2>16.3	Storage and Handling</h2>
<ul>
<li>PHARMACIST: Prior to Dispensing: Store in a refrigerator, 2°C to 8°C (36°F to 46°F).</li>
<li>PATIENT: Store at room temperature at or below 25°C (77°F).</li>
<li>Protect from freezing.</li>
<li>Keep out of the reach of children.</li>
<li>Keep container tightly closed.</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-14"></a><p></p>
<h1>17	PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Italics">See <a href="#Information">FDA-approved patient labeling (Patient Information)</a></span></p>
<ul>
<li>Patients who develop <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> such as severe <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> or <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> should discontinue use and contact their physician immediately. </li>
<li>ACANYA Gel may cause irritation such as <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, scaling, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, or burning, especially when used in combination with other topical <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> therapies. </li>
<li>Excessive or prolonged exposure to sunlight should be limited. To minimize exposure to sunlight, a hat or other clothing should be worn. Sunscreen may also be used. </li>
<li>ACANYA Gel may bleach hair or colored fabric.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="Information"></a><a name="section-15"></a><p></p>
<p class="First"><span class="Bold">PATIENT INFORMATION <br>ACANYA<span class="Sup">®</span><span class="Italics"> (AH-CAN΄-YAH)</span><br>(clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/2.5%</span></p>
<table width="75%">
<col align="left" valign="middle" width="100%">
<tbody class="Headless"><tr class="First Last"><td class="Lrule Rrule" align="left">IMPORTANT: For use on skin only (topical use).  Do not get ACANYA Gel in your mouth, eyes, or vagina, or on your lips.</td></tr></tbody>
</table>
<p>Read the Patient Information that comes with ACANYA Gel before you start using it and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your doctor about your medical condition or your treatment.</p>
<p><span class="Bold">What is ACANYA Gel?</span></p>
<p>ACANYA Gel is a prescription medicine used on the skin (topical) to treat <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne vulgaris</span> in people 12 years and older.  ACANYA Gel contains clindamycin phosphate and benzoyl peroxide.</p>
<p>It is not known if ACANYA Gel is safe and effective for use longer than 12 weeks.</p>
<p>It is not known if ACANYA Gel is safe and effective in children under 12 years of age.</p>
<p><span class="Bold">Who should not use ACANYA Gel?</span></p>
<p><span class="Bold">Do not use ACANYA Gel if you have:</span></p>
<ul>
<li>Crohn's disease</li>
<li><span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span></li>
<li>had <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of the colon (<span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>), or  severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> with past antibiotic use</li>
</ul>
<p>Talk with your doctor if you are not sure if you have one of these conditions.</p>
<p><span class="Bold">What should I tell my doctor before using ACANYA Gel?</span></p>
<p><span class="Bold">Before using ACANYA Gel, tell your doctor about all of your medical conditions, including if you:</span></p>
<ul>
<li><span class="Bold">have any allergies.</span></li>
<li><span class="Bold">have any other medical conditions.</span></li>
<li>
<span class="Bold">are pregnant or planning to become pregnant.</span> It is not known if ACANYA Gel will harm your unborn baby.</li>
<li>
<span class="Bold">are breastfeeding or plan to breast-feed.</span> It is not known if ACANYA Gel passes into your breast milk. One of the medicines in ACANYA Gel contains clindamycin. Clindamycin when taken by mouth or by injection has been reported to appear in breast milk. You and your doctor should decide whether you will use ACANYA Gel while breast-feeding.  </li>
</ul>
<p><span class="Bold">Tell your doctor about all the medicines and skin products you use.</span> Especially tell your doctor if you will have surgery with general anesthesia.  One of the medicines in ACANYA Gel (clindamycin) can affect how certain medicines work when used in general anesthesia.  </p>
<ul>
<li>ACANYA Gel should not be used with products that contain erythromycin.</li>
<li>Other skin and topical <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> products may increase the irritation of your skin when used with ACANYA Gel.</li>
</ul>
<p>Know the medicines you take. Keep a list of them and show it to your doctor and pharmacist when you get a new medicine.</p>
<p><span class="Bold">How should I use ACANYA Gel?</span></p>
<ul>
<li>Use ACANYA Gel exactly as prescribed. </li>
<li>Your doctor will tell you how long to use ACANYA Gel. </li>
<li>Throw away (discard) any unused ACANYA Gel. </li>
</ul>
<p><span class="Bold">Instructions for applying ACANYA Gel</span></p>
<ul><li>Apply ACANYA Gel to your face one time each day as prescribed.<br> <ol>
<li>Before you apply ACANYA Gel, wash your face gently with a mild soap, rinse with warm water, and pat your <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">skin dry</span>.</li>
<li>To apply ACANYA Gel to your face, use the pump to dispense one pea-sized amount of ACANYA Gel onto your fingertip. See <a href="#fig1">Figure 1</a>. One pea-sized amount of ACANYA Gel should be enough to cover your entire face.<table width="100%">
<col align="center" valign="middle" width="100%">
<tbody class="Headless"><tr class="Botrule First Last Toprule"><td align="center">
<span class="Bold">Figure 1</span><br><a name="fig1"></a><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3dcd2c96-72b1-4a9f-b65c-08198d63b7df&amp;name=acanya-03.jpg">
</td></tr></tbody>
</table>
</li>
<li>Dot the one pea-sized amount of ACANYA Gel onto six areas of your face (chin, left cheek, right cheek, nose, left forehead, right forehead). See <a href="#fig2">Figure 2</a>. <table width="100%">
<col align="center" valign="middle" width="100%">
<tbody class="Headless"><tr class="Botrule First Last Toprule"><td align="center">
<span class="Bold">Figure 2</span><br><a name="fig2"></a><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3dcd2c96-72b1-4a9f-b65c-08198d63b7df&amp;name=acanya-04.jpg">
</td></tr></tbody>
</table>
</li>
<li>After applying the ACANYA Gel this way, spread the gel over your face and gently rub it in.  It is important to spread the gel over your whole face.</li>
<li>Wash your hands with soap and water after applying ACANYA Gel.</li>
<li>If your doctor tells you to put ACANYA Gel on other areas of your skin with <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, be sure to ask how much you should use.</li>
<li>Do not get ACANYA Gel in your mouth, eyes, or nose, or on your lips. If this occurs, rinse the affected area with warm water and call your doctor right away if the area becomes very red, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itchy</span>, tender, or swollen.</li>
<li>Do not get ACANYA Gel on cuts or open <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span>.</li>
<li>Do not use more ACANYA Gel than prescribed.</li>
</ol>
</li></ul>
<p><span class="Bold">What should I avoid while using ACANYA Gel?</span></p>
<ul>
<li>Limit your time in sunlight. Avoid using tanning beds or sun lamps. If you have to be in sunlight, wear a wide-brimmed hat or other protective clothing, and a sunscreen with SPF 15 rating or higher. Your doctor can give you more information about why this is important.</li>
<li>Do not wash your face more than 2 to 3 times a day. Washing your face too often or scrubbing it may make your <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> worse.</li>
<li>Avoid getting ACANYA Gel in your hair or on colored fabric. ACANYA Gel may bleach hair or colored fabric.</li>
</ul>
<p><span class="Bold">What are possible side effects with ACANYA Gel?</span></p>
<p><span class="Bold">ACANYA Gel can cause serious side effects including:</span></p>
<ul>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span> of the colon (<span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>).</span> Stop using ACANYA Gel and call your doctor right away if you have severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">watery diarrhea</span>, or <span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span>.</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span>. </span>Stop using ACANYA Gel, call your doctor and get help right away if you have any of the following symptoms:<ul class="Disc">
<li>severe <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span></li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your face, eyes, lips, tongue or throat</li>
<li>trouble breathing</li>
</ul>
</li>
</ul>
<p><span class="Bold">Common side effects with ACANYA Gel include:</span></p>
<ul><li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4280604" conceptname="Skin irritation">Skin irritation</span>.</span> Stop using ACANYA Gel and call your doctor if you have a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or your skin becomes very red, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itchy</span> or swollen. </li></ul>
<p>Talk to your doctor about any side effect that bothers you or that does not go away.</p>
<p>These are not all the possible side effects with ACANYA Gel. Ask your doctor or pharmacist for more information.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</p>
<p>You may also report side effects to Valeant Pharmaceuticals North America LLC at 1-800-321-4576.</p>
<p><span class="Bold">How should I store ACANYA Gel?</span></p>
<ul>
<li>Store ACANYA Gel at room temperature at or below 25°C (77°F). </li>
<li>The expiration date of ACANYA Gel is 10 weeks from the date you fill your prescription.</li>
<li>Safely throw away expired ACANYA Gel.</li>
<li>Do not freeze.</li>
<li>Keep the container tightly closed.</li>
</ul>
<p><span class="Bold">Keep ACANYA Gel and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General information about ACANYA Gel</span></p>
<p>Medicines are sometimes prescribed for conditions that are not mentioned in Patient Information leaflets. Do not use ACANYA Gel for a condition for which it was not prescribed. <span class="Bold">Do not give ACANYA Gel to other people, even if they have the same condition you have.  It may harm them.</span></p>
<p>This leaflet summarizes the most important information about ACANYA Gel. If you would like more information, talk with your doctor. You can also ask your doctor or pharmacist for information about ACANYA Gel that is written for healthcare professionals.</p>
<p>For more information about ACANYA Gel, call 1-800-321-4576.</p>
<p><span class="Bold">What are the ingredients in ACANYA Gel?</span></p>
<p><span class="Bold">Active Ingredients:</span> clindamycin phosphate 1.2% and benzoyl peroxide 2.5%</p>
<p><span class="Bold">Inactive Ingredients:</span> purified water, carbomer 980, propylene glycol, and potassium hydroxide</p>
<p>Manufactured by:<br>Valeant Pharmaceuticals International Inc.<br>Laval, Quebec H7L 4A8</p>
<p>For: <br>Valeant Pharmaceuticals North America LLC<br>Bridgewater, NJ 08807 USA</p>
<p>Made in Canada</p>
<p>U.S. Patents 5,733,886 and 8,288,434</p>
<p>This Patient Information has been approved by the U.S. Food and Drug Administration. </p>
<p>Revised 02/2014<br>9387200</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-16"></a><p></p>
<p class="First"><span class="Bold"><br><br>PRINCIPAL DISPLAY PANEL - 50 gram Pump Label</span></p>
<p><span class="Bold">NDC </span>13548-132-50
                  </p>
<p><span class="Bold">Acanya</span><span class="Sup">®</span><br>(Clindamycin Phosphate and<br>Benzoyl Peroxide) Gel, 1.2%/2.5%</p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">FOR TOPICAL USE ONLY</span></p>
<p><span class="Bold">One premixed 50-gram pump dispenser</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 50 gram Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3dcd2c96-72b1-4a9f-b65c-08198d63b7df&amp;name=acanya-50g-pump-label.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ACANYA 		
					</strong><br><span class="contentTableReg">clindamycin phosphate and benzoyl peroxide gel</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:13548-132</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Clindamycin Phosphate</strong> (Clindamycin) </td>
<td class="formItem">Clindamycin</td>
<td class="formItem">10 mg  in 1 g</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>Benzoyl Peroxide</strong> (Benzoyl Peroxide) </td>
<td class="formItem">Benzoyl Peroxide</td>
<td class="formItem">25 mg  in 1 g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Carbomer Homopolymer Type C</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>propylene glycol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>potassium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:13548-132-50</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">50 g in 1 BOTTLE, PUMP; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA050819</td>
<td class="formItem">07/26/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Coria Laboratories
							(010977972)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Valeant Pharmaceuticals North America LLC (042230623)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Valeant Pharmaceuticals International, Inc</td>
<td class="formItem"></td>
<td class="formItem">245141858</td>
<td class="formItem">MANUFACTURE(13548-132)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 2/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>ab864bd9-aa9c-4c53-801c-921ceed03df1</div>
<div>Set id: 3dcd2c96-72b1-4a9f-b65c-08198d63b7df</div>
<div>Version: 8</div>
<div>Effective Time: 20140228</div>
</div>
</div> <div class="DistributorName">Coria Laboratories</div></p>
</body></html>
